Perimed

03/03/2026

Peripheral artery disease (PAD) affects about 20% of the UK population aged 55-75 — more than 2 million people. Two-thirds are asymptomatic. People are unaware they are ill, but this can be prevented in 85% of cases with, for example, early intervention.

Every year in the UK, nearly 7,000 people lose a limb because of diabetic foot complications. For many, amputation marks the beginning of a steep decline — with a five-year mortality rate of 50%, exceeding that of several common cancers.

Our partnership with Healthcare 21 aims to support improved clinical decision-making and patient outcomes — aligned with the priorities of the NHS and broader preventative care initiatives. We look forward to working closely with the team at HC 21 UK.

👉 Read more about the partnership and what it means for clinicians and patients from our global distributor manager Liuting Xu

To ensure long-term availability and continuity of the TcpO2 electrode delivered with PeriFlux 6000 instruments, Perimed is bringing the manufacturing of this sensor in-house.

12/02/2026

As a medtech supplier, we know that continuity is vital. Assuming our products deliver accurate measurements, they’re of little use if clinicians cannot obtain new parts when their old ones pass their sell-by date, or when consumables on which the measurements rely cannot be replaced.

That’s why Perimed has decided to bring the manufacture of TcpO2 electrodes in-house, together with the membrane kit needed to keep electrodes clean — augmenting our TcpO2 offering to encompass all elements needed for robust measurements.

Our CEO explains how this step supports clinicians by securing supply, maintaining compatibility with established specifications, and enabling TcpO2 use across different clinical environments, including hyperbaric settings.

Read more here:
👉

To ensure long-term availability and continuity of the TcpO2 electrode delivered with PeriFlux 6000 instruments, Perimed is bringing the manufacturing of this sensor in-house.

20/01/2026

🚀2026 is off to a strong start at Perimed. Last week, we shared the news of our new CFO, who will help shape our financial strategy for a sustainable future. This week, we’re welcoming two new members to our Nordic Sales team: Ola Kristiansson and Rickard Rönnqvist.

At the same time, Sara Gyllensporre, well known to many of our Nordic customers, is stepping into a new role as Clinical Application Specialist. With more than 16 years at Perimed, Sara brings deep expertise and insight that will help customers get even more from their instruments — for the best possible patient outcomes.

👉

The perfect start to 2026 — two new territory managers in the form of Ola Kristiansson and Rickard Rönnqvist. Let's get to know them!

14/01/2026

🚀 Perimed welcomes Christoffer Berggren as our new CFO!

Strong financial leadership is key as we aim to leverage new technologies to continue supporting clinicians and researchers with innovative products and solutions. Christoffer brings extensive experience in financial structures, transparency, and disciplined growth, and will play a central role in our leadership team.

👉 Read more about Christoffer, his experience, and his vision for Perimed: https://www.perimed-instruments.com/blog/perimed-appoints-new-cfo/

Financial leadership is a keystone of Perimed’s growth journey. The appointment of Christoffer Berggren as Chief Financial Officer (CFO) aligns our commercial momentum with financial discipline to ensure sustainable growth.

14/11/2025

Today is a reminder that diabetes is more than a metabolic disease — it’s a vascular one. By uncovering the hidden side of diabetes, microcirculation, it's possible to make a difference between a limb saved and a limb lost.

In this post, we talk about why microcirculation matters and its role in limb preservation for people with diabetes.

On World Diabetes Day, we are reminded that diabetes is more than a metabolic disease characterized by chronic hyperglycemia. It is a significant risk factor for circulatory disorders, and uncovering the hidden microcirculatory component provides clinicians with crucial insight.

02/10/2025

Running Windows in a regulated industry like healthcare or finance? 🏥💳

Unsupported software is one of the most common entry points for cyberattacks. That’s why many organizations have already upgraded to Windows 11, are in the process of migrating, or have purchased extended support from Microsoft.

But it’s not just about operating systems. Every application in your stack — including the software that comes with medical devices — needs ongoing updates and patching to stay secure.

At Perimed, we’ve verified that our supported software works with Windows 11 ✅ — helping you to protect patient data and ensure system security.

Running unsupported software exposes your hospital and patients to cyberattacks, WannaCry, which brought the UK's NHS to a standstill, exploited a known vulnerability, which most large organizations simply didn't have the time to patch before the attack occurred.

23/09/2025

In oncoplastic reconstructive surgery, nearly 30% of implant procedures result in a complication — many due to poor tissue perfusion. Finding practical solutions isn’t easy, but clinical evidence is emerging.

👨‍⚕️ Dr. Ralser and his team at University Hospital Bonn, Germany, tested laser speckle contrast imaging (LSCI) with our PeriCam PSI in 73 reconstructions. Their findings suggest surgeons can use LSCI for rapid, real-time perfusion insights — helping to reduce complication rates.

👉 Read Jimmy Bakker’s latest blog post to see the key takeaways, plus a link to the full webinar with Dr. Ralser

https://www.perimed-instruments.com/blog/filling-the-technology-gap-in-oncoplastic-surgery-with-perfusion-imaging/

Nearly 30% of all breast implant procedures result in a complication. Dr. Damian Ralser has conducted an observational study using LSCI to determine the potential of this technology to reduce complication rates.

05/07/2024

Research finding suggests possible new markers for more accurate risk prediction of HFpEF in women with type II diabetes (T2D). In a study, conducted with participants from the Hoorn Diabetes Care System, and carried out by several researchers, including Etto Eringa, found that women with T2D with poor blood vessel response to insulin have a greater risk of developing HFpEF.

Using PeriIont — Perimed’s iontophoresis solution — to administer the insulin, researchers were able to assess microvascular dysfunction by comparing baseline perfusion and response with real-time data and images generated by PeriCam PSI.

If you’re attending IVBM 2024, don’t miss Eringa’s session, where he will talk about their research, or you can read more about it here: https://doi.org/10.1093/eurheartj/ehac544.787

04/07/2024

At an IVBM 2024 poster session, Sébastien Foulquier presented his and Ph.D. candidate Sara Lambrichts’ research on cerebral vascular dysfunction in relation to heart failure with preserved ejection fraction (HFpEF). Using a PeriCam PSI imaging device, they observed notable differences in brain blood flow responses to whisker stimulation between lean and obese rats. PeriCam PSI leverages laser speckle contrast imaging (LSCI) delivering perfusion data and images in real-time.

03/07/2024

Attending the International Vascular Biology Meeting (IVBM 2024) in Amsterdam this week? Don’t miss the chance to meet our product managers, Jimmy Bakker and Maltha Anatasha. They’re on hand to demonstrate how our imaging and laser Doppler technologies provide invaluable insights, driving new discoveries and the development of innovative therapies.

Whether you're attending or not, if vascular dysfunction interests you, check out our most recent webinar: "Microvascular Dysfunction as an Early Marker of Cardiometabolic Diseases," featuring Associate Professor Boy Houben. He shares ground-breaking findings from his work with the Maastricht Study. https://www.perimed-instruments.com/webinars-why-measure-microcirculation-2/

# hashtag hashtag hashtag

16/04/2024

Perimed's instrument PeriFlux 6000 EPOS, used to measure participants in the SCAPIS study, reveals ground-breaking findings on the link between early changes in microcirculation and the risk of cardiovascular disease.

This unique study led by the Swedish Heart-Lung Foundation measured almost 3,000 people aged 50-65. The results show the risk of developing cardiovascular disease to be five times higher for people with the lowest microcirculatory response compared with those with a high response.

The press release is in Swedish, but you can read the full report published by the European Journal of Preventive Cardiology https://academic.oup.com/eurjpc/advance-article/doi/10.1093/eurjpc/zwae052/7604139 and more about PeriFlux 6000 EPOS
https://www.perimed-instruments.com/content/periflux-6000-epos/

https://www.mynewsdesk.com/se/hjart-lungfonden/pressreleases/unik-ny-metod-kan-visa-risk-foer-hjaert-kaerlsjukdom-genom-att-belysa-huden-3316575

En banbrytande metod som involverar att belysa huden på underarmen har visat sig kunna avslöja ökad risk för hjärt-kärlsjukdom. Det visar en studie vid...

27/03/2024

Don't miss the first session of our webinar series: Why measure microcirculation. Jean-Luc Cracowski will talk about microcirculation and its role in clinical assessment. Register to get a link to attend or watch the recording at your convenience.
9ade1dcf-8c2d-44e0-aa6f-9ffb672b103b@2ced85d9-65ef-46c4-8bd8-796ac8c7bddb" rel="ugc" target="_blank">https://events.teams.microsoft.com/event/9ade1dcf-8c2d-44e0-aa6f-9ffb672b103b@2ced85d9-65ef-46c4-8bd8-796ac8c7bddb